Tacrolimus in solid organ transplantation: an update.
Shapiro
R
R
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pennsylvania, USA.
D000328:Adult; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use*; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006085:Graft Survival; D016027:Heart Transplantation / Q000276:immunology / Q000401:mortality; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality; D016031:Liver Transplantation / Q000276:immunology / Q000401:mortality; D016040:Lung Transplantation / Q000276:immunology / Q000401:mortality; D016035:Pancreas Transplantation / Q000276:immunology / Q000401:mortality; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D014181:Transplantation Immunology; D014481:United States
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus